Join the Oncology Voice Network. Join for Free
Biosimilars: what the oncologist should know
biosimilars extrapolation monoclonal antibodies oncologic biosimilars

Biosimilars: what the oncologist should know


Share This Article


Summary

  • As originator biologic medicines lose patent protection, biopharmaceutical companies are developing biosimilars.
  • Biosimilars are similar versions of costly and complex therapies aimed at providing more affordable treatment options.
  • Many biosimilars are now approved worldwide, with several more expected to be introduced soon.
  • Clinicians need to become familiar with biosimilars, understanding their development and differences from originator biologics and generics.
  • This review aims to equip clinicians with the necessary knowledge to understand and use biosimilars, particularly in treating oncologic diseases.

An increasingly greater proportion of life-saving therapies now include complex biologics. More and more cancer therapeutics and medications used for inflammatory diseases are counted among this growing class of agents. However, biologics can be expensive and as originator biologics begin to lose their patent protection, some biopharmaceutical companies are directing resources on developing ‘similar’ versions of these costly and complex therapies. One of the goals of developing these molecules, known as biosimilars, is to provide additional treatment alternatives. Several biosimilars are now approved worldwide for treatment of cancer and supportive care.

As more biosimilars become available, it is important that clinicians and healthcare providers (HCPs) familiarize themselves with this new category of products and understand how they are developed. Considering that cancer treatments are expected to form a major proportion of biosimilar products, and biologics are often a critical part of oncology treatments, it will be particularly important for oncologists to educate themselves in this area...

Click for Source
biosimilars, extrapolation, monoclonal antibodies , oncologic biosimilars

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Evaluating External Validity of Oncology Biosimilar Safety Studies
OVN Avatar Gregory S. Calip, PharmD, MPH, PhD, Ivy P. Altomare, MD, Jenny S. Guadamuz, MSPH, PhD

Evaluating External Validity of Oncology Biosimilar Safety Studies

Article
Medical Oncologists’ Knowledge and Perspectives on the Use of Biosimilars in the United States
OVN Avatar John Devin Peipert, PhD, Karen Kaiser, PhD, Sheetal Kircher, MD, George J. Greene, PhD, Sara Shaunfield, PhD, Katherina Hauner, PhD, David Cella, PhD, and Daniel K. Mroczek, PhD

Medical Oncologists’ Knowledge and Perspectives on the Use of Biosimilars in the United States

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Explore OVN